Kiryat Hadassah Medical Center
P.O. Box 12000
14 articles with KAHR Medical
Prof. Hagop M. Kantarjian, M.D., Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, has joined KAHR's clinical advisory board.
Data for DSP107, first-in-class bi-functional CD47x41BB targeting compound, to be presented on December 5, 2020
KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, announced that Aron Knickerbocker has been appointed Director and that Bryan Jennings has been appointed Chief Financial Officer of KAHR.
KAHR Medical Announces FDA Clearance of IND Application for DSP107, anti-CD47 Candidate for the Treatment of Solid Tumors
Phase I/II study in patients with solid tumors expected to commence in Q3 2020 at leading sites in the United States
Funds will be used for advancing the Company's next generation immuno-oncology drug candidates, including lead anti-CD47 product for the treatment of solid tumors through Phase I/II study in addition to advancing preclinical pipeline
KAHR Medical Announces Clinical Trial Collaboration to Evaluate DSP107 in Combination With a PD-L1 Checkpoint Inhibitor in Advanced Lung Cancer Patients
KAHR Medical announced a new clinical collaboration with Roche.
Hadasit Bio-Holdings Ltd. Portfolio Companies - ProtAb Ltd. and KAHR Medical to Receive NIS 10.7 Million (Over $2.8 Million USD) in Additional Government Grants
KAHR Medical And Cobra BioManufacturing Partner to Develop Trans Signal Converter Protein Production
KAHR Medical Raises $500K From Hadasit Bio Holdings and the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor of Israel